187 related articles for article (PubMed ID: 36932237)
21. Growth factor treatment prior to low-dose total body irradiation increases donor cell engraftment after bone marrow transplantation in mice.
Noach EJ; Ausema A; Dillingh JH; Dontje B; Weersing E; Akkerman I; Vellenga E; de Haan G
Blood; 2002 Jul; 100(1):312-7. PubMed ID: 12070042
[TBL] [Abstract][Full Text] [Related]
22. The contribution of cytotoxic and noncytotoxic function by donor T-cells that support engraftment after allogeneic bone marrow transplantation.
Jiang Z; Adams GB; Hanash AM; Scadden DT; Levy RB
Biol Blood Marrow Transplant; 2002; 8(11):588-96. PubMed ID: 12463477
[TBL] [Abstract][Full Text] [Related]
23. Additional monoclonal antibody (mAB) injections can replace thymic irradiation to allow induction of mixed chimerism and tolerance in mice receiving bone marrow transplantation after conditioning with anti-T cell mABs and 3-Gy whole body irradiation.
Tomita Y; Sachs DH; Khan A; Sykes M
Transplantation; 1996 Feb; 61(3):469-77. PubMed ID: 8610363
[TBL] [Abstract][Full Text] [Related]
24. A partial conditioning approach to achieve mixed chimerism in the rat: depletion of host natural killer cells significantly reduces the amount of total body irradiation required for engraftment.
Neipp M; Gammie JS; Exner BG; Li S; Chambers WH; Pham SM; Ildstad ST
Transplantation; 1999 Aug; 68(3):369-78. PubMed ID: 10459540
[TBL] [Abstract][Full Text] [Related]
25. Comparison of gamma and x-ray irradiation for myeloablation and establishment of normal and autoimmune syngeneic bone marrow chimeras.
Wittenborn TR; Fahlquist Hagert C; Ferapontov A; Fonager S; Jensen L; Winther G; Degn SE
PLoS One; 2021; 16(3):e0247501. PubMed ID: 33730087
[TBL] [Abstract][Full Text] [Related]
26. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide.
Luznik L; Jalla S; Engstrom LW; Iannone R; Fuchs EJ
Blood; 2001 Dec; 98(12):3456-64. PubMed ID: 11719388
[TBL] [Abstract][Full Text] [Related]
27. Methyl-Guanine-Methyl-Transferase Transgenic Bone Marrow Transplantation Allows N,N-bis(2-chloroethyl)-Nitrosourea Driven Donor Mixed-Chimerism Without Graft-Versus-Host Disease, and With Donor-Specific Allograft Tolerance.
Hu M; Kramer B; Zhang GY; Wang YM; Watson D; Howden B; McCowage G; Alexander IE; Gunning P; Alexander SI
Transplantation; 2015 Dec; 99(12):2476-84. PubMed ID: 26177088
[TBL] [Abstract][Full Text] [Related]
28. Prevention of acute graft-vs-host disease by a single low-dose cyclophosphamide injection following allogeneic bone marrow transplantation.
Prigozhina TB; Elkin G; Khitrin S; Slavin S
Exp Hematol; 2008 Dec; 36(12):1750-9. PubMed ID: 18809241
[TBL] [Abstract][Full Text] [Related]
29. An immunoablative regimen of fludarabine and cyclophosphamide prevents fully MHC-mismatched murine marrow graft rejection independent of GVHD.
Petrus MJ; Williams JF; Eckhaus MA; Gress RE; Fowler DH
Biol Blood Marrow Transplant; 2000; 6(2A):182-9. PubMed ID: 10816026
[TBL] [Abstract][Full Text] [Related]
30. Low Radiation Dose and Low Cell Dose Increase the Risk of Graft Rejection in a Canine Hematopoietic Stem Cell Transplantation Model.
Lange S; Steder A; Glass Ä; Killian D; Wittmann S; Machka C; Werner J; Schäfer S; Roolf C; Junghanss C
Biol Blood Marrow Transplant; 2016 Apr; 22(4):637-643. PubMed ID: 26802322
[TBL] [Abstract][Full Text] [Related]
31. A second prophylactic MHC-mismatched bone marrow transplantation protects against rat acute myeloid leukemia (BNML) without lethal graft-versus-host disease.
Nestvold JM; Omdal BK; Dai KZ; Martens A; Benestad HB; Vaage JT; Rolstad B
Transplantation; 2008 Jan; 85(1):102-11. PubMed ID: 18192919
[TBL] [Abstract][Full Text] [Related]
32. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
Russell CA
Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093
[TBL] [Abstract][Full Text] [Related]
33. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease.
Johnson BD; Drobyski WR; Truitt RL
Bone Marrow Transplant; 1993 Apr; 11(4):329-36. PubMed ID: 8485480
[TBL] [Abstract][Full Text] [Related]
34. Combination of intra-bone marrow-bone marrow transplantation and subcutaneous donor splenocyte injection diminishes risk of graft-versus-host disease and enhances survival rate.
Shi M; Adachi Y; Cui Y; Li M; Lian Z; Zhang Y; Yanai S; Shima C; Imai Y; Ikehara S
Stem Cells Dev; 2011 May; 20(5):759-68. PubMed ID: 20954841
[TBL] [Abstract][Full Text] [Related]
35. Dose and timing of interleukin (IL)-12 and timing and type of total-body irradiation: effects on graft-vs.-host disease inhibition and toxicity of exogenous IL-12 in murine bone marrow transplant recipients.
Sykes M; Pearson DA; Taylor PA; Szot GL; Goldman SJ; Blazar BR
Biol Blood Marrow Transplant; 1999; 5(5):277-84. PubMed ID: 10534057
[TBL] [Abstract][Full Text] [Related]
36. Radiation protocols determine acute graft-versus-host disease incidence after allogeneic bone marrow transplantation in murine models.
Schwarte S; Bremer M; Fruehauf J; Sorge Y; Skubich S; Hoffmann MW
Int J Radiat Biol; 2007 Sep; 83(9):625-36. PubMed ID: 17654104
[TBL] [Abstract][Full Text] [Related]
37. Interleukin-10 administration decreases survival in murine recipients of major histocompatibility complex disparate donor bone marrow grafts.
Blazar BR; Taylor PA; Smith S; Vallera DA
Blood; 1995 Feb; 85(3):842-51. PubMed ID: 7833486
[TBL] [Abstract][Full Text] [Related]
38. Durable mixed allogeneic chimerism and tolerance by a nonlethal radiation-based cytoreductive approach.
Colson YL; Li H; Boggs SS; Patrene KD; Johnson PC; Ildstad ST
J Immunol; 1996 Oct; 157(7):2820-9. PubMed ID: 8816385
[TBL] [Abstract][Full Text] [Related]
39. Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance allows for persistent antileukemic reactivity without severe graft-versus-host disease.
Johnson BD; Truitt RL
Blood; 1995 Jun; 85(11):3302-12. PubMed ID: 7756664
[TBL] [Abstract][Full Text] [Related]
40. New strategies in allogeneic stem cell transplantation: immunotherapy using irradiated allogeneic T cells.
Waller EK; Boyer M
Bone Marrow Transplant; 2000 May; 25 Suppl 2():S20-4. PubMed ID: 10933181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
